Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828661 | 0.91 | MTNR1A (0.48) | MTNR1AMTNR1BCHRM2CHRM1CHRM3 | |
| SCHEMBL4453170 | 0.88 | MAOB (0.55) | MTNR1AMTNR1BRAB9ANPC1GAA | |
| SCHEMBL3690675 | 0.87 | MTNR1A (0.65) | MTNR1AMTNR1BCHRM2CHRM1CHRM3 | |
| SCHEMBL5354570 | 0.87 | FDFT1 (0.57) | — | |
| SCHEMBL3418637 | 0.86 | ALDH1A1 (0.62) | RAB9AALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL21090366 | 0.86 | FDFT1 (0.47) | MTNR1AMTNR1BCNR1POLBCA1 | |
| SCHEMBL6202190 | 0.85 | PLAAT3 (0.48) | MTNR1AMTNR1BCNR1POLBCA1 | |
| SCHEMBL1295923 | 0.85 | MTNR1A (0.50) | MTNR1AMTNR1BRAB9AALDH1A1HTT | |
| SCHEMBL67569 | 0.85 | CYP2D6 (0.58) | ALDH1A1HTT | |
| SCHEMBL31506266 | 0.85 | CYP2D6 (0.58) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617811-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4175951-B1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230339896-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339896-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| CN-116332910-A | 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof | 江苏威凯尔医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-102056894-A | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| EP-1581498-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004047739-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | MTNR1A 1195/4885MTNR1B 1714/4885CHRM2 1624/4885 |
| US-12617811-B2 | HPK1 inhibitors and uses thereof | MAP2K4, MAP2K1, MAP2K3 | MTNR1A 4529/4885MTNR1B 4274/4885CHRM2 4198/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | MTNR1A 4501/4885MTNR1B 4571/4885CHRM2 4880/4885 |
| US-20230339896-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, MAPKAPK5, MLKL | MTNR1A 4694/4885MTNR1B 4572/4885CHRM2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.